The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression

Secreted protein acidic and rich in cysteine (SPARC), or osteonectin, belongs to the family of matricellular proteins that modulate cell–matrix interactions and cellular functions. SPARC is highly expressed in melanoma, and we reported that SPARC promotes epithelial/mesenchymal‐like changes and cell migration. Here, we used siRNA and conditional shRNA to investigate the contribution of tumor‐derived SPARC to melanoma cell growth in vitro and in vivo. We found that depletion of SPARC induces G2/M cell cycle arrest and tumor growth inhibition with activation of p53 and induction of p21Cip1/Waf1 acting as a checkpoint, preventing efficient mitotic progression. In addition, we demonstrate that reduced mesenchymal features and the invasive potential of SPARC‐silenced cells are independent of p21Cip1/Waf1 induction and cell cycle arrest. Importantly, overexpression of SPARC reduces p53 protein levels and leads to an increase in cell number during exponential growth. Our findings indicate that in addition to its well‐known function as a mediator of melanoma cell migration and tumor–host interactions, SPARC regulates, in a cell‐autonomous manner, cell cycle progression and proliferation through the p53/p21Cip1/Waf1 pathway.

[1]  D. Dinh,et al.  Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells , 2010, Cell Death and Differentiation.

[2]  T. Nakatsura,et al.  Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G1 arrest induction , 2010, Cancer science.

[3]  P. Fortina,et al.  p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo , 2009, Proceedings of the National Academy of Sciences.

[4]  H. Frierson,et al.  The role of SPARC in the TRAMP model of prostate carcinogenesis and progression , 2009, Oncogene.

[5]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[6]  P. Abbe,et al.  Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. , 2009, Cancer research.

[7]  M. Colombo,et al.  Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. , 2008, Cancer research.

[8]  M. Colombo,et al.  Matricellular proteins at the crossroad of inflammation and cancer. , 2008, Cancer letters.

[9]  A. Mauviel,et al.  JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis , 2008, Pigment cell & melanoma research.

[10]  E. Sage,et al.  A prototypic matricellular protein in the tumor microenvironment—Where there's SPARC, there's fire , 2008, Journal of cellular biochemistry.

[11]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[12]  James M. Roberts,et al.  CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .

[13]  B. Gardiner,et al.  Osteonectin downregulates E‐cadherin, induces Osteopontin and Focal adhesion kinase activity stimulating an invasive melanoma phenotype , 2007, International journal of cancer.

[14]  M. Tang,et al.  A Novel Interaction between Procaspase 8 and SPARC Enhances Apoptosis and Potentiates Chemotherapy Sensitivity in Colorectal Cancers* , 2007, Journal of Biological Chemistry.

[15]  O. Podhajcer,et al.  SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. , 2007, The Journal of investigative dermatology.

[16]  N. Said,et al.  Normalization of the Ovarian Cancer Microenvironment by SPARC , 2007, Molecular Cancer Research.

[17]  D. Bigner,et al.  Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases , 2007, Oncogene.

[18]  A. Sánchez-Aguilera,et al.  A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. , 2007, Cancer research.

[19]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[20]  C. Iacobuzio-Donahue,et al.  Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Jane Goodall,et al.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.

[22]  P. Abbe,et al.  SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. , 2006, Cancer research.

[23]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[24]  Mariano J. Alvarez,et al.  Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. , 2005, Cancer research.

[25]  M. Herlyn,et al.  Adhesion, migration and communication in melanocytes and melanoma. , 2005, Pigment cell research.

[26]  P. Abbe,et al.  HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1 , 2005, Oncogene.

[27]  L. Larue,et al.  Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression , 2005, Nature.

[28]  D. Bigner,et al.  Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation* , 2004, Journal of Biological Chemistry.

[29]  E Helene Sage,et al.  Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. , 2004, Molecular cancer research : MCR.

[30]  M. Colombo,et al.  Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma , 2003, The Journal of experimental medicine.

[31]  E Helene Sage,et al.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.

[32]  J. Piette,et al.  Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts , 2003, The EMBO journal.

[33]  R. Brekken,et al.  Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. , 2003, The Journal of clinical investigation.

[34]  O. Volpert,et al.  SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. , 2002, Cancer research.

[35]  P. Bornstein,et al.  Matricellular proteins: extracellular modulators of cell function. , 2002, Current opinion in cell biology.

[36]  R. Berkowitz,et al.  SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. , 2001, The American journal of pathology.

[37]  E. Sage,et al.  SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. , 2001, The Journal of clinical investigation.

[38]  G. Stark,et al.  Regulation of the G2/M transition by p53 , 2001, Oncogene.

[39]  G. Stark,et al.  p130/E2F4 Binds to and Represses the cdc2 Promoter in Response to p53* , 2001, The Journal of Biological Chemistry.

[40]  R. Medema,et al.  p21 Inhibits Thr161 Phosphorylation of Cdc2 to Enforce the G2 DNA Damage Checkpoint* , 2000, The Journal of Biological Chemistry.

[41]  J. Pietenpol,et al.  p53 Regulation of G2 Checkpoint Is Retinoblastoma Protein Dependent , 2000, Molecular and Cellular Biology.

[42]  S. Jackson,et al.  Regulation of p53 in response to DNA damage , 1999, Oncogene.

[43]  D. Massi,et al.  Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. , 1999, Human pathology.

[44]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[45]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[46]  O. Podhajcer,et al.  Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.

[47]  Stephen J. Elledge,et al.  Cell Cycle Checkpoints: Preventing an Identity Crisis , 1996, Science.

[48]  N. Hayward,et al.  Mutation and expression of the p53 gene in human malignant melanoma , 1994, Melanoma research.

[49]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[50]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[51]  W. Cavenee,et al.  Mutation and expression of the p53 gene in malignant melanoma cell lines , 1993, International journal of cancer.

[52]  P. Higgins,et al.  Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: regulation via a TGF-beta-dependent pathway. , 1993, Experimental cell research.

[53]  Andrea S. Llera,et al.  The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host , 2008, Cancer and Metastasis Reviews.

[54]  M. Herlyn,et al.  Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. , 2002, Cancer research.

[55]  R. Brekken,et al.  SPARC, a matricellular protein: at the crossroads of cell-matrix communication. , 2001, Matrix biology : journal of the International Society for Matrix Biology.